Table 8.
Association between six types of statins and first-time sarcopenia among CKD patients in Taiwan.
| Variable | Sarcopenia HR | p Value | Adjust Sarcopenia HR | p Value |
|---|---|---|---|---|
| (95% CI) | (95% CI) | |||
| Statin Non-Use | 1 | 1 | ||
| Statin use | 0.709 (0.645–0.780) | <0.0001 | 0.753 (0.671–0.845) | <0.0001 |
| Hydrophilic Statin | ||||
| Pravastatin | 0.681 (0.542–0.855) | 0.0010 | 0.766 (0.607–0.968) | 0.0257 |
| Fluvastatin | 0.785 (0.655–0.940) | 0.0086 | 0.883 (0.733–1.064) | 0.1917 |
| Rosuvastatin | 0.407 (0.330–0.501) | <0.0001 | 0.448 (0.362–0.555) | <0.0001 |
| Lipophilic Statin | ||||
| Lovastatin | 0.831 (0.690–1.001 | 0.0508 | 0.924 (0.762–1.121) | 0.4238 |
| Simvastatin | 0.775 (0.667–0.902) | 0.0010 | 0.850 (0.724–0.997) | 0.0452 |
| Atorvastatin | 0.702 (0.620–0.795) | <0.0001 | 0.791 (0.691–0.906) | 0.0007 |
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval. Models adjusted gender, age, income, urbanization, comorbidity.